Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based …

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC …

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the “Warrants”), …

Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw to Scientific Advisory Board

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company’s Scientific Advisory Board.

Helix BioPharma Corp. Reports Voting Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and special meeting of shareholders held on January 28, 2021 (the “Meeting”). In accordance with section 11.3 of National …

Helix BioPharma Corp. Responds to Market Activity

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price …

Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.

Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG (“CAIAC”) for the Company’s remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), for gross …

Helix BioPharma Corp. announces fiscal 2021 first quarter results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.